Manhattan Research Releases Physician Digital Media Planning Guide

Manhattan ResearchWhile most marketers have accepted that nearly all physicians are online today, the more difficult part is figuring out where to find these physicians on the World Wide Web. Finding the right promotional mix for connecting with physicians can be a challenging proposition, as physicians use third-party sites - such as the WebMD Professional Network, the New England Journal of Medicine, or specialty specific sites - more frequently than they use pharma-owned properties. As a result, brands realize that it is essential to connect with physicians through a variety of online professional resources - but figuring out where to find these physicians can prove difficult.

"Physician Digital Media Landscape: Connecting with Physicians Through Online Professional Resources," is part of Manhattan Research's ePharma Physician® market research and advisory service and provides a roadmap for physician marketers and media planners. The report explores the top professional medical websites, specialty sites, print and online medical journals, and professional email newsletters for primary care physicians, pediatricians, oncologists, cardiologists, gastroenterologists, infectious disease/HIV physicians, rheumatologists, and OB/GYNs. "Physician Digital Media Landscape" also includes interviews with industry experts, case studies, and a look at the future of physician marketing.

"This guide is an invaluable resource for anyone interested in understanding how physicians gather information online today," says Meredith Ressi, Vice President of Research at Manhattan Research. "Many companies are struggling to understand the appropriate promotional mix across the vast range of online resources used by physicians. This data shows the professional sources physicians rely on to gather professional medical information."

Report Outline
Title: Physician Digital Media Landscape: Connecting with Physicians through Online Professional Resources

Introduction
Physician Digital Media Outlook for Primary Care Physicians, Pediatricians, Oncologists, Cardiologists, Gastroenterologists, Infectious Disease/HIV Physicians, Rheumatologists, and OB/GYNs

  • Professional Medical Websites
  • Specialty Websites
  • Professional Journals
  • Professional Email Newsletters

Top Online Physician Professional Online Resource Summary

Physician Digital Media Outlook and Strategy

Conclusion and Key Takeaways

For an excerpt from the module and more information about its contents, please visit: www.manhattanresearch.com/products/Research_Modules/Physician/physician-digital-media-landscape.aspx

Access to the "Physician Digital Media Landscape" research module is immediately available to subscribers of Manhattan Research's ePharma Physician® v9.0 market research and strategic advisory service. For more information about subscribing to this service and gaining access to the in-depth physician market data and analysis, visit www.manhattanresearch.com/products/Strategic_Advisory/ePP.

About ePharma Physician® v9.0
ePharma Physician® v9.0 was conducted via online survey methodology in Q2 2009 among 1,517 online practicing U.S. physicians. Since 2002, the study has determined the leading online physician destinations based on the number of physician visitors as well as the content satisfaction of those who visit. ePharma Physician® gives insight to the physician digital resource and communication mix of over twenty specialist segments, including topics such as:

  • Product and corporate pharmaceutical websites
  • Specialty-specific sites, online journals, newsletters, and online conferences
  • Interactive detailing, live remote rep, customer service portals, and email communication
  • Web 2.0 technologies such as blogs, podcasts, wikis, and online communities

For additional product and subscription information, please visit www.manhattanresearch.com/products/Strategic_Advisory/ePP.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.decisionresourcesinc.com.

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...